Miyagi Y, Imai N, Sasatomi T, Yamada A, Mine T, Katagiri K, Nakagawa M, Muto A, Okouchi S, Isomoto H, Shirouzu K, Yamana H, Itoh K
Department of Surgery, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830-0011, Japan.
Clin Cancer Res. 2001 Dec;7(12):3950-62.
The tumor-rejection antigen SART3 possesses two antigenic epitopes (SART3(109-118) and SART3(315-323)) capable of inducing HLA-A24-restricted and tumor-specific CTLs. To determine its safety and ability to generate antitumor immune responses, 12 patients with advanced colorectal cancer were administered s.c. vaccinations of these peptides. No severe adverse events were associated with the vaccinations. Significant levels of increased cellular immune responses to both HLA-A24+ colon cancer cells and the vaccinated peptide were observed in the postvaccination peripheral blood mononuclear cells in 7 of 11 and 7 of 10 patients tested, respectively, and the higher responses were observed in those patients vaccinated with the highest dose (3 mg/injection) of the peptides. These results encourage further development of SART3 peptide vaccine for colorectal cancer patients.
肿瘤排斥抗原SART3具有两个抗原表位（SART3(109 - 118)和SART3(315 - 323)），能够诱导HLA - A24限制性和肿瘤特异性细胞毒性T淋巴细胞（CTL）。为了确定其安全性和产生抗肿瘤免疫反应的能力，对12例晚期结直肠癌患者进行了这些肽的皮下接种。接种疫苗未出现严重不良事件。在分别测试的11例患者中的7例和10例患者中的7例的接种后外周血单个核细胞中，观察到对HLA - A24 +结肠癌细胞和接种肽的细胞免疫反应显著增强，并且在接种最高剂量（3毫克/注射）肽的患者中观察到更高的反应。这些结果鼓励进一步开发用于结直肠癌患者的SART3肽疫苗。
Zotero 插件